Skip to main content

Market Overview

Recap: Sage Therapeutics Q4 Earnings



Shares of Sage Therapeutics (NASDAQ:SAGE) remained unaffected after the company reported Q4 results.

Quarterly Results

Earnings per share increased 659.69% over the past year to $18.19, which may not compare to the estimate of ($0.35).

Revenue of $1,109,000,000 higher by 56481.63% year over year, which beat the estimate of $55,340,000.


Sage Therapeutics hasn't issued any earnings guidance for the time being.

Sage Therapeutics hasn't issued any revenue guidance for the time being.

Conference Call Details

Date: Feb 24, 2021

Time: 08:00 AM

ET Webcast URL:

Price Action

52-week high: $98.39

Company's 52-week low was at $25.01

Price action over last quarter: Up 2.79%

Company Overview

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-547, it is in Phase 3 clinical trials for super-refractory status epilepticus; and the SAGE-217 program which is in Phase 2 clinical trials for post-partum depression, essential tremor, Parkinson's disease and major depressive disorder. The company is also developing several other compounds for treatment that is in the early stage of development.


Related Articles (SAGE)

View Comments and Join the Discussion!

Posted-In: BZI-RecapsEarnings News

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at